Study Summary
This trial looks at whether an MRI scan enhanced with ferumoxytol can show whether there is inflammation in the brain of children with cancer.
Eligible Conditions
- Childhood Brain Tumor
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: Days 2-4
Day 1
Iron concentration measurements
Days 2-4
Macrophages on histopathology
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Diagnostic (ferumoxytol-enhanced MRI)
1 of 1
Experimental Treatment
10 Total Participants · 1 Treatment Group
Primary Treatment: Diagnostic (ferumoxytol-enhanced MRI) · No Placebo Group · Phase < 1
Diagnostic (ferumoxytol-enhanced MRI)Experimental Group · 4 Interventions: Surgery, Diagnostic (ferumoxytol-enhanced MRI), Ferumoxytol, Tissue Analysis · Intervention Types: Procedure, DiagnosticTest, Drug, Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Surgery
1999
Completed Phase 3
~2060
Ferumoxytol
FDA approved
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: days 2-4
Who is running the clinical trial?
Michael IvLead Sponsor
1 Previous Clinical Trials
10 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,098 Previous Clinical Trials
41,145,797 Total Patients Enrolled
Eligibility Criteria
Age Any Age · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments